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The prevalence of cytomegalovirus (CMV) infec-
tions ranges between 50% and 85% in adults in the 
United States, and its epidemiology varies in differ-
ent regions of the world and between socioeconomic 
and age groups. In Portugal, no study has been car-
ried out to date to determine the prevalence of CMV 
in the general population. Under the second National 
Serological Survey conducted in continental Portugal 
in 2001–2002, we estimated the prevalence of individ-
uals with antibodies to CMV using indirect immunoflu-
orescence to detect virus-specific IgG. The population 
sample included 2,143 individuals of both sexes and 
different ages from all 18 districts in Portugal. The 
national seroprevalence of CMV was determined as 
77%. We analysed the proportion of CMV IgG by sex, 
age group and district of residence. This was the first 
nationally representative study of seroprevalence of 
CMV in Portugal. The results of the study indicate that 
CMV infection is highly prevalent in the population 
and occurs mainly in the first years of life.
Introduction
Cytomegalovirus (CMV) is a common virus with no 
known seasonal predominance and with a prevalence 
that ranges between 50% and 85% of adults in the 
United States [1-3]. The epidemiology of CMV varies in 
different regions of the world and in different socioeco-
nomic and age groups [3-5].
CMV establishes a latent state following primary infec-
tion, reactivating when there are changes in immune 
status [6,7]. CMV infections are most often asympto-
matic, but when symptomatic, can cause a syndrome 
similar to clinical and haematological infectious mono-
nucleosis. The virus is excreted through body fluids, 
and the most common modes of transmission are via 
the oropharyngeal and genital tract, although trans-
mission can also occur through breast milk, organ 
transplant or blood transfusions [8-11].
CMV primary infection occurs mostly in childhood and 
adolescence, but primary infections are also observed 
in adults [3,11-14]. The infection is important in certain 
risk groups such as immunocompromised individuals 
and pregnant women. In immunocompromised indi-
viduals, CMV infection is the leading cause of mor-
bidity and mortality, especially in connection with 
transplants, haemodialysis, cancer, immunosuppres-
sive medication and infection with human immunode-
ficiency virus (HIV) [8]. Transplacental transmission 
can occur and primary infection in the first 16 weeks 
of pregnancy is associated with higher rate of dam-
age in fetal development [15-20]. In primary maternal 
infection, the probability of transmission of CMV to 
the fetus is approximately 30% to 40%. In women with 
CMV reactivation during pregnancy the probability of 
fetal CMV transmission decreases to approximately 
0.5% to 1.4% [21-24]. In developed countries, CMV is 
a major cause of congenital infection, with an inci-
dence of 0.4% to 2.2% of total live births per year, and 
is responsible for neonatal morbidity and mortality 
[19,23,25-27]. The congenital CMV infection is asymp-
tomatic in the neonatal period (the first 28 days of life) 
in approximately 85% to 90% of infants, but nearly 5% 
to 15% of these infants show late sequelae during the 
first years of life, typically hearing deficits and visual 
impairments [22,28-30]. Approximately 10% to 15% of 
infants with congenital CMV infection are symptomatic 
at birth, with manifestations including growth retarda-
tion, jaundice, purpura, hepatosplenomegaly, micro-
cephaly, intracerebral calcifications, and retinitis. The 
risk of long-term neurodevelopmental disabilities is 
high in these children and include microcephaly, hear-
ing loss, motor deficits, cerebral palsy, mental retar-
dation, seizures, ocular abnormalities and learning 
disabilities [23,31-34].
In a recent review of priorities for vaccine development, 
the Institute of Medicine of the National Academy of 
Sciences in the United States concluded that in terms 
of healthcare costs and years of life and disability 
saved, a vaccine against CMV infection should be a pri-
ority [35,36].
In Portugal, the prevalence of CMV in the population 
and the incidence of CMV congenital infection have 
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not previously been determined. However, in 2003, 
preliminary results of a prospective study indicated 
that the proportion of CMV congenital infections was 
0.7% in a consecutive population of newborns in the 
area of Lisbon, as determined using the gold standard 
technique, shell vial culture of urine [37]. According to 
a survey by Paixão et al. [38] that screened for CMV 
congenital infection by PCR of blood samples obtained 
from Guthrie cards, the proportion of congenital infec-
tion by CMV was 1.1% in Portugal and 0.7% in the 
region of Lisbon in the period from August 2003 to 
September 2004.
The second National Serological Survey conducted in 
continental Portugal in 2001–2002 was carried out 
with two objectives: firstly, to determine the preva-
lence of individuals with antibodies to vaccine-prevent-
able diseases, as a means of evaluating the national 
immunisation programme, and secondly, to determine 
the prevalence of individuals with antibodies to infec-
tions deemed important in terms of public health. As 
part of the second National Serological Survey, we 
estimated the proportion of individuals with CMV anti-
bodies in Portugal in 2002-2003 in order to assess the 
prevalence of CMV in the population [39].
Methods
Sampling 
The main sample frame that was used to study the 
immunity to diseases included in the national immuni-
sation programme was calculated to be nationally rep-
resentative and to adequately cover all age groups, at a 
sample size of 3,304 individuals of both sexes, homo-
geneously distributed in eight age groups: 2–4, 5–9, 
10–14, 15–19, 20–29, 30–44, 45–64, and ≥65 years. 
Each age group included individuals from each of the 18 
districts of mainland Portugal, to a number proportion-
ally representative for the population of each district. 
Between 2002 and 2003, the national immunisation 
programme recruited 3,525 participants at 38 private 
and public serum collections points, distributed in all 
18 districts of mainland Portugal. Individuals were 
invited to participate until the district and age grids 
prepared were completed. For the participation of indi-
viduals, a fact sheet was prepared with the objectives 
and benefits of the study and informed consent was 
obtained either from the participants themselves or 
from their legal representatives [39].
For our specific study on the prevalence of CMV, we 
used a sub-sample of 2,143 individuals. Serum sam-
ples were taken from the same batch collected during 
2002–2003 and analysed in 2003–2004 for the pres-
ence of CMV-specific antibodies.
Serological analyses
IgG antibodies specific for CMV were detected by indi-
rect immunofluorescence, using commercial reagents 
(Merifluor CMV IgG, US) according to the manufac-
turer’s instructions. Samples were added to a layer 
of human fibroblasts fixed on glass slides on which 
approximately 10% of cells are infected with CMV 
strain AD169, and the formation of antigen-antibody 
complex is viewed using a fluorescent dye. Uninfected 
fibroblasts on the same slide were used as an internal 
control of the specificity of the test. The tests were val-
idated with negative and positive control sera. The use 
of reference sera ensured the reproducibility of results 
between batches. According to the manufacturer, the 
test has 97% sensitivity, 100% specificity, 100% pre-
dictive value of a positive test and 99% predictive 
value of a negative test.
Statistical analysis
Statistical analysis consisted in the determination 
of absolute and relative frequencies (percentages). 
Binomial confidence intervals were calculated using 
the exact method that uses the relationship between 
the F and Binomial distributions attributed to Bliss and 
Brownlee as described by Zar [40].
Table 
Individuals IgG-positive for cytomegalovirus, by sex, 
Portugal, 2002-2003 (n=2,143) 
Sex
Study 
participants
n
CMV-positive
n (%)
95% confidence 
interval
Male 860  622(72.3) 69.2–75.3
Female 1,283  1,029(80.2) 77.9–82.4
Total 2,143 1,651(77%) 75.2–78.8
CMV: cytomegalovirus.
Figure 1
Percentage of individuals IgG-positive results for 
cytomegalovirus, by age and sex, Portugal, 2002-2003 
(n=2,143)
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Results
In a total of 2,143 individuals, 1,651 had IgG antibodies 
to CMV (77%, 95% confidence interval (CI): 75.2–78.8) 
and 492 were seronegative (23%, 95%: CI 21.2–24.8). 
Among the male participants, 622 (72.3%) were CMV-
positives and among the female participants 1,029 
(80.2%) were CMV-positives (Table).
When analysing the distribution of CMV IgG-positive 
individuals by age, 66.5% of children in the youngest 
age group (2–4 years) were shown to have antibodies. 
The percentage of seropositive individuals was similar 
in age group of 5-9 year-olds and 10-14 year-olds with 
65.1% and 64.9%, respectively, and then increased 
with age, reaching 71.3% in the age group of 15–19 
year-olds, 80.5% in the 30–44 year-olds and 95.6% in 
the oldest group (≥65 years). The percentage of males 
and females with CMV IgG in each age group is shown 
in Figure 1.
Analysis of the distribution of CMV IgG-positive indi-
viduals by district of residence showed that only one 
of the 18 districts of Portugal, Viana do Castelo, had a 
prevalence of less than 70% of seropositive individuals. 
The highest prevalence of CMV-positive residents was 
found in the districts of Guarda, Braga and Vila Real, 
with 89.5%, 86.4% and 85.2%, respectively (Figure 2).
Discussion
In Portugal, the second National Serological Survey 
has established, for the first time, the prevalence of 
individuals with CMV-specific IgG. The results of this 
study indicated that CMV infection was highly preva-
lent in the population (77%), similar to what has been 
described for other countries, and that it occurred pre-
dominantly in the first years of life [1,3,41-46].
Seroprevalence for CMV between the age of two and 
four years was high, with 66.5% of IgG-positive children 
in this age group (95% CI: 59.3–73.2). Children younger 
than two years were not included in the study and con-
clusions on the situation at that age can therefore not be 
drawn. However, breastfeeding is known to be a signifi-
cant source of CMV transmission to children and plays an 
important role in the epidemiology of CMV infection as 
CMV is reactivated during lactation in nearly every sero-
positive mother [47-49]. The proportion of infants who 
acquire CMV during the first year of life is directly related 
to the prevalence of maternal infection and to the pro-
portion of mothers who breastfeed. In countries where 
breastfeeding is widely practiced and most mothers are 
seropositive, for example in south and south-eastern 
Europe, regions of Asia, Africa and Latin America, more 
than 50% of infants acquire CMV within the first year of 
life [8,50]. The seroprevalence found in the age group 
between two and four years (66.5%) was probably the 
result not only of transmission via breastmilk but also 
of oral transmission from other children and from sero-
positive adults they are in close contact with when they 
start attending day care centers at that age [51,52]. This 
was similar to the seroprevalence of 53.8% found in sev-
eral studies performed in children of that age in Brazil 
(region of São Paulo) [53]. It was higher than that in Italy 
(region of Parma, 28% at two years of age) and Finland 
(41% at eight years of age) and lower than in Venezuela 
(region of Valencia; 83.3% between two and four years 
of age) and Turkey (region of Antalya, 82.1% in children 
between one and six years of age) [41,54-56].
The antibody prevalence in children at school age (age 
groups 5–9 years and 10–14 years) was similar to that 
at pre-school age, but increased further to 71.3% (95% 
CI: 64.8–77.2) in the age group between 15 and 19 
years, which corresponds to a greater sexual exposure, 
in addition to close non-sexual contact [3,8,13,57]. 
The antibody prevalence in this age group was identi-
cal to that in the 20–29 year-olds. Studies with simi-
lar age groups conducted in other countries, such as 
the United States, Japan, France, England, Poland and 
Russia, describe seroprevalences ranging between 
51.5% and 78.0% [3,44,58-62].
Figure 2
Proportion of individuals IgG-positive for cytomegalovirus, 
by district of residence, Portugal, 2002-2003 (n=2,143)
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The prevalence of individuals with CMV IgG gradually 
increased further in the three oldest age groups, with 
values of 80.5% (95% CI: 75.6%–84.8%), 92.2% (95% 
CI: 88.7%–94.9%) and 95.6% (95% CI: 92.4%–97.7%), 
suggesting that sexual transmission was an impor-
tant route of transmission of the virus in the popula-
tion [8,63,64]. Another recognised source of adult CMV 
infection are children. Children infected with CMV shed 
virus in saliva and urine for years, providing an oppor-
tunity for continued spread to other children and sus-
ceptible adults (close relatives and day care workers) 
[8,51,65–67].
IgG-positivity was equally common in both sexes in the 
age groups of 2–4 and 5–9 year-olds, while in the older 
age groups, females were more likely to be IgG-positive 
than males. The statistically significant difference of 
8% between males and females in the prevalence of 
individuals with CMV IgG could be explained by the 
fact that women may have more contact with children. 
This horizontal mode of transmission presents a risk to 
mothers, pregnant women and those with occupations 
associated with exposure to children, such as teachers 
and day care providers [23,63,68,69].
Nevertheless, it should be noted that in our study, 
24.5% and 18.5% of women of reproductive age (from 
20 to 29 years and 30 to 44 years, respectively) were 
susceptible to CMV, which led us to conclude that there 
is a considerable risk for congenital infection due to 
maternal primary CMV infection, which leads to fetal 
infection in approximately 40% of cases [11,16].
Possible approaches to preventing congenital CMV 
infections include improved hygiene behaviour of 
seronegative pregnant women, administration of CMV 
hyperimmune globulin (HIG) to pregnant women with 
primary infection, and vaccines, once available, admin-
istered to girls or women before pregnancy [70].
Several studies have been done to determine whether 
changing protective behaviour prevents child-to-
mother transmission of CMV during pregnancy [71-
74]. The United States Centers for Disease Control and 
Prevention recommend that seronegative pregnant 
women assume that children are secreting CMV in their 
urine or saliva. They advise on simple hygiene such 
as frequent hand washing, wearing gloves for specific 
childcare tasks and avoiding intimate contact with 
their child such as sharing utensils, food or towels, and 
kissing on or near the mouth [75-77].
Despite advances in the diagnosis of maternal-fetal 
CMV infection and approaches to prevent congenital 
CMV, an effective prenatal therapy is unavailable. A 
prospective, non-randomised study of pregnant women 
who acquired CMV infection during pregnancy and who 
received passive immunisation with CMV HIG, showed 
that this therapy was associated with a significantly 
reduced risk of congenital CMV disease and infection 
and had no adverse effects [70,78,79]. Recent case 
reports supported safe administration of oral ganciclo-
vir to mothers of CMV-infected fetuses, with no tera-
togenic side effects when given in the early stages of 
pregnancy [70,80,81]. The efficacy of ganciclovir still 
remains to be defined in controlled trials. Other early 
experience with treatment of intrauterine CMV infec-
tion using maternal oral administration of valaciclovir 
showed that it decreased the viral load in fetal blood 
significantly and could potentially also reduce the 
morbidity of prolonged intrauterine infection [82]. The 
absence of adverse effects or teratogenecity of val-
aciclovir is compatible with its clinical use, but a well-
designed randomised controlled trial is needed.
Currently, there is no approved vaccine for CMV, but 
two vaccines are in phase II studies: one is a recom-
binant vaccine containing the major envelope glycopro-
tein B of the virus with the adjuvant MF59 (gB/MF59) 
that induces high levels of neutralising antibodies, is 
safe and immunogenic in adults and infants, prevent-
ing also maternal CMV infection [36,83]. The other 
vaccine is the live attenuated CMV Towne strain that 
stimulates neutralising antibodies comparable to 
those induced by wild type virus and protects renal 
transplant patients from severe CMV after transplanta-
tion [78,84].
The main interventions for the prevention of CMV infec-
tion should be aimed at women who wish to become 
pregnant, women who care for children and immuno-
compromised individuals. These individuals in whom 
exposure to CMV can be most detrimental will be the 
target groups for possible administration of a future 
vaccine.
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